These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 34298687)

  • 1. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention.
    Orabi D; Berger NA; Brown JM
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).
    Duseja A; Singh SP; De A; Madan K; Rao PN; Shukla A; Choudhuri G; Saigal S; Shalimar ; Arora A; Anand AC; Das A; Kumar A; Eapen CE; Devadas K; Shenoy KT; Panigrahi M; Wadhawan M; Rathi M; Kumar M; Choudhary NS; Saraf N; Nath P; Kar S; Alam S; Shah S; Nijhawan S; Acharya SK; Aggarwal V; Saraswat VA; Chawla YK
    J Clin Exp Hepatol; 2023; 13(2):273-302. PubMed ID: 36950481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatty liver diseases, bile acids, and FXR.
    Zhu Y; Liu H; Zhang M; Guo GL
    Acta Pharm Sin B; 2016 Sep; 6(5):409-412. PubMed ID: 27709009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ménage à trois of autophagy, lipid droplets and liver disease.
    Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
    Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD.
    Vitulo M; Gnodi E; Rosini G; Meneveri R; Giovannoni R; Barisani D
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease.
    Puengel T; Liu H; Guillot A; Heymann F; Tacke F; Peiseler M
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease.
    Choudhary NS; Kumar N; Duseja A
    J Clin Exp Hepatol; 2019; 9(6):731-739. PubMed ID: 31889755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear receptors and nonalcoholic fatty liver disease.
    Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
    Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
    Qiu YY; Zhang J; Zeng FY; Zhu YZ
    Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Khan FZ; Perumpail RB; Wong RJ; Ahmed A
    World J Hepatol; 2015 Aug; 7(18):2155-61. PubMed ID: 26328027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.
    Ballestri S; Nascimbeni F; Romagnoli D; Baldelli E; Lonardo A
    Adv Ther; 2016 Mar; 33(3):291-319. PubMed ID: 26921205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.
    Song Q; Zhang X
    Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy.
    Polyzos SA; Chrysavgis L; Vachliotis ID; Chartampilas E; Cholongitas E
    Semin Cancer Biol; 2023 Aug; 93():20-35. PubMed ID: 37149203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent updates on targeting the molecular mediators of NAFLD.
    Wang J; Wang L; Zhang XJ; Zhang P; Cai J; She ZG; Li H
    J Mol Med (Berl); 2023 Feb; 101(1-2):101-124. PubMed ID: 36792729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota.
    Chen L-p; Zhang L-f; Liu S; Hua H; Zhang L; Liu B-c; Wang R-r
    Microbiol Spectr; 2024 Jun; 12(6):e0197923. PubMed ID: 38647315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges.
    Ahmad MI; Khan MU; Kodali S; Shetty A; Bell SM; Victor D
    J Hepatocell Carcinoma; 2022; 9():477-496. PubMed ID: 35673598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies.
    Wang GY; Zhang XY; Wang CJ; Guan YF
    World J Gastroenterol; 2023 Jan; 29(1):75-95. PubMed ID: 36683713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.